
Claims

1. Compounds of general formula (1),



(1),

wherein

wherein

R³ denotes ~~a group selected from among 3-8 membered heterocycloalkyl, C_{6-10}aryl and 5-12 membered heteroaryl~~pyridyl, optionally substituted by one or more identical or different **R⁴**; and

R¹ denotes a group selected from among ~~C_{6-10}aryl~~phenyl and ~~5-12 membered heteroaryl~~ pyridyl, optionally substituted by one or more identical or different **R⁵** and

R² denotes ~~a group selected from among hydrogen,~~ C_{1-4}alkyl, ~~C_{3-8}cycloalkyl, 3-8 membered heteroalkyl, 3-8 membered heterocycloalkyl, OR^v, NR^vR^{v1}, SR^v, CF_3, CN, NC and NO_2,~~ and

each **R⁴** denotes a group selected from among ~~**R^a** and **R^b**~~ methyl, ethyl, amino, methylamino, ethylamino; and

~~each **R^a** independently of one another denotes hydrogen or a group selected from among C_{1-6}alkyl, 2-6 membered heteroalkyl, C_{1-6}haloalkyl, C_{3-10}cycloalkyl, C_{4-16}cycloalkylalkyl, C_{6-10}aryl, C_{7-16}arylalkyl, 5-12 membered heteroaryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, **R^a** optionally being substituted by one or more identical or different **R^b** and/or **R^{e4}**;~~

~~each **R^b** denotes a suitable group and is selected independently of one another from among =O, OR^e, C_{1-3}haloalkyloxy, OCF_3, $OCHF_2$, =S, SR^e, $=NR^e$, $=NOR^e$, $=NNR^eR^{e1}$, $=NN(R^g)C(O)NR^eR^{e1}$, NR^eR^{e1}, ONR^eR^{e1}, $N(OR^e)R^{e1}$, $N(R^g)NR^eR^{e1}$, halogen, CF_3, CN, NC, OCN, SCN, NO, NO_2, $=N_2$, N_3, $S(O)R^e$, $S(O)OR^e$, $S(O)_2R^e$, $S(O)_2OR^e$, $S(O)NR^eR^{e1}$, $S(O)_2NR^eR^{e1}$, $OS(O)R^e$, $OS(O)_2R^e$, $OS(O)_2OR^e$, $OS(O)NR^eR^{e1}$, $OS(O)_2NR^eR^{e1}$, $C(O)R^e$, $C(O)OR^e$, $C(O)SR^e$, $C(O)NR^eR^{e1}$, $C(O)N(R^g)NR^eR^{e1}$, $C(O)N(R^g)OR^e$, $C(NR^g)NR^eR^{e1}$, $C(NOH)R^e$, $C(NOH)NR^eR^{e1}$,~~

$-OC(O)R^e$, $-OC(O)OR^e$, $-OC(O)SR^e$, $-OC(O)NR^eR^{e1}$, $-OC(NR^g)NR^eR^{e1}$, $-SC(O)R^e$, $-SC(O)OR^e$, $-SC(O)NR^eR^{e1}$, $-SC(NR^g)NR^eR^{e1}$, $-N(R^g)C(O)R^e$, $-N[C(O)R^e][C(O)R^{e1}]$, $-N(OR^g)C(O)R^e$, $-N(R^g)C(NR^{g1})R^e$, $-N(R^g)N(R^{g1})C(O)R^e$, $-N[C(O)R^{e2}]NR^eR^{e1}$, $-N(R^g)C(S)R^e$, $-N(R^g)S(O)R^e$, $-N(R^g)S(O)OR^e$, $-N(R^g)S(O)_2R^e$, $-N[S(O)_2R^e][S(O)_2R^{e1}]$, $-N(R^g)S(O)_2OR^e$, $-N(R^g)S(O)_2NR^eR^{e1}$, $-N(R^g)[S(O)_2]_2R^e$, $-N(R^g)C(O)OR^e$, $-N(R^g)C(O)SR^e$, $-N(R^g)C(O)NR^eR^{e1}$, $-N(R^g)C(O)NR^{g1}NR^eR^{e1}$, $-N(R^g)N(R^{g1})C(O)NR^eR^{e1}$, $-N(R^g)C(S)NR^eR^{e1}$, $-[N(R^g)C(O)]_2R^e$, $-N(R^g)[C(O)]_2R^e$, $-N\{[C(O)]_2R^e\}\{[C(O)]_2R^{e1}\}$, $-N(R^g)[C(O)]_2OR^e$, $-N(R^g)[C(O)]_2NR^eR^{e1}$, $-N\{[C(O)]_2OR^e\}\{[C(O)]_2OR^{e1}\}$, $-N\{[C(O)]_2NR^eR^{e1}\}\{[C(O)]_2NR^{e2}R^{e3}\}$, $-[N(R^g)C(O)]_2OR^e$, $-N(R^g)C(NR^{g1})OR^e$, $-N(R^g)C(NOH)R^e$, $-N(R^g)C(NR^{g1})SR^e$, $-N(R^g)C(NR^{g1})NR^eR^{e1}$, $-N(R^g)C(=N-CN)NR^eR^{e1}$ and $-N=C(R^g)NR^eR^{e1}$ and

each $\mathbf{R^e}$, $\mathbf{R^{e1}}$, $\mathbf{R^{e2}}$, $\mathbf{R^{e3}}$ and $\mathbf{R^{e4}}$ independently of one another denotes hydrogen or a group selected from among C_{1-6}alkyl, 2-6 membered heteroalkyl, C_{1-6}haloalkyl, C_{3-10}cycloalkyl, C_{4-16}cycloalkylalkyl, C_{6-10}aryl, C_{7-16}arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, $\mathbf{R^e}$, $\mathbf{R^{e1}}$, $\mathbf{R^{e2}}$, $\mathbf{R^{e3}}$ and $\mathbf{R^{e4}}$ independently optionally being substituted by one or more identical or different $\mathbf{R^d}$ and/or $\mathbf{R^{e4}}$, where $\mathbf{R^e}$ together with $\mathbf{R^g}$ and/or $\mathbf{R^{e1}}$ and/or $\mathbf{R^{e2}}$ and/or $\mathbf{R^{e3}}$ or $\mathbf{R^{e2}}$ together with $\mathbf{R^{e3}}$ may form a 3-8 membered heterocyclalkyl residue via a shared C-, N- O- or S-atom, and

each $\mathbf{R^d}$ denotes a suitable group and is selected independently of one another from among =O, OR^e, C_{1-3}haloalkyloxy, OCF_3, OCHF2, =S, SR^e, $=NR^e$, $=NOR^e$, $=NNR^eR^{e1}$, $=NN(R^{g2})C(O)NR^eR^{e1}$, NR^eR^{e1}, ONR^eR^{e1}, $N(R^{g2})NR^eR^{e1}$, halogen, CF_3, CN, NC, OCN, SCN, NO, NO_2, $=N_2$, N_3, $S(O)R^e$, $S(O)OR^e$, $S(O)_2R^e$, $S(O)_2OR^e$, $S(O)NR^eR^{e1}$, $S(O)_2NR^eR^{e1}$, $OS(O)R^e$, $OS(O)_2R^e$, $OS(O)_2OR^e$, $OS(O)NR^eR^{e1}$, $OS(O)_2NR^eR^{e1}$, $C(O)R^e$, $C(O)OR^e$, $C(O)SR^e$, $C(O)NR^eR^{e1}$, $C(O)N(R^{g2})NR^eR^{e1}$, $C(O)N(R^{g2})OR^e$, $C(NR^{g2})NR^eR^{e1}$, $C(NOH)R^e$, $C(NOH)NR^eR^{e1}$, $OC(O)R^e$, $OC(O)OR^e$, $OC(O)SR^e$, $OC(O)NR^eR^{e1}$, $OC(NR^{g2})NR^eR^{e1}$, $SC(O)R^e$, $SC(O)OR^e$, $SC(O)NR^eR^{e1}$, $SC(NR^{g2})NR^eR^{e1}$, $N(R^{g2})C(O)R^e$, $N[C(O)R^e][C(O)R^{e1}]$, $N(OR^{g2})C(O)R^e$, $N(R^{g2})C(NR^{g3})R^e$, $N(R^{g2})N(R^{g3})C(O)R^e$, $N[C(O)R^{e2}]NR^eR^{e1}$, $N(R^{g2})C(S)R^e$, $N(R^{g2})S(O)R^e$, $N(R^{g2})S(O)OR^e$ $N(R^{g2})S(O)_2R^e$, $N[S(O)_2R^e][S(O)_2R^{e1}]$, $N(R^{g2})S(O)_2OR^e$, $N(R^{g2})S(O)_2NR^eR^{e1}$, $N(R^{g2})[S(O)_2]_2R^e$,

$-N(R^{g2})C(O)OR^{e}$, $-N(R^{g2})C(O)SR^{e}$, $-N(R^{g2})C(O)NR^{e}R^{e1}$, $-N(R^{g2})C(O)NR^{g3}NR^{e}R^{e1}$, $-N(R^{g2})N(R^{g3})C(O)NR^{e}R^{e1}$, $-N(R^{g2})C(S)NR^{e}R^{e1}$, $-[N(R^{g2})C(O)][N(R^{g3})C(O)]R^{e}$, $-N(R^{g2})[C(O)]_2R^{e}$, $-N\{[C(O)]_2R^{e}\}\{[C(O)]_2R^{e1}\}$, $-N(R^{g2})[C(O)]_2OR^{e}$, $-N(R^{g2})[C(O)]_2NR^{e}R^{e1}$, $-N\{[C(O)]_2OR^{e}\}\{[C(O)]_2OR^{e}\}$, $-N\{[C(O)]_2NR^{e}R^{e1}\}\{[C(O)]_2NR^{e2}R^{e3}\}$, $-[N(R^{g3})C(O)][N(R^{g3})C(O)]OR^{e}$, $-N(R^{g2})C(NR^{g3})OR^{e}$, $-N(R^{g2})C(NOH)R^{e}$, $-N(R^{g2})C(NR^{g3})SR^{e}$, $-N(R^{g2})C(NR^{g3})NR^{e}R^{e1}$, $-N(R^{g2})C(=N-CN)NR^{e}R^{e1}$ and $-N=C(R^{g2})NR^{e}R^{e1}$

each R^{e}, R^{e1}, R^{e2}, R^{e3} and R^{e4} independently of one another denotes hydrogen or a group selected from among C_{1-6}alkyl, 2-6 membered heteroalkyl, C_{1-6}haloalkyl, C_{3-10}cycloalkyl, C_{4-16}cycloalkylalkyl, C_{6-10}aryl, C_{7-16}arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where R^{e} together with R^{g2} and/or R^{e1} and/or R^{e2} and/or R^{e3} or R^{e2} together with R^{e3} may form a 3-8 membered heterocyclalkyl residue via a shared C-, N-, O- or S-atom, and where R^{e}, R^{e1}, R^{e2}, R^{e3} and R^{e4} independently optionally being substituted by one or more identical or different R^{f} and/or R^{g6}, and

each R^{f} denotes a suitable group and in each case is selected independently of one another from among =O, OR^{g}, C_{1-3}haloalkyloxy, OCF_3, $OCHF_2$, =S, SR^{g}, $=NR^{g4}$, $=NOR^{g4}$, $=NNR^{g4}R^{g5}$, $=NN(R^{h})C(O)NR^{g4}R^{g5}$, $NR^{g4}R^{g5}$, $ONR^{g4}R^{g5}$, $N(R^{h})NR^{g4}R^{g5}$, halogen, CF_3, CN, NC, OCN, SCN, NO, NO_2, $=N_2$, N_3, $S(O)R^{g4}$, $S(O)OR^{g4}$, $S(O)_2R^{g4}$, $S(O)_2OR^{g4}$, $S(O)NR^{g4}R^{g5}$, $S(O)_2NR^{g4}R^{g5}$, $OS(O)R^{g4}$, $OS(O)_2R^{g4}$, $OS(O)_2OR^{g4}$, $OS(O)NR^{g4}R^{g5}$, $OS(O)_2NR^{g4}R^{g5}$, $C(O)R^{g4}$, $C(O)OR^{g4}$, $C(O)SR^{g4}$, $C(O)NR^{g4}R^{g5}$, $C(O)N(R^{h})NR^{g4}R^{g5}$, $C(O)N(R^{h})OR^{g4}$, $C(NR^{h})NR^{g4}R^{g5}$, $C(NOH)R^{g4}$, $C(NOH)NR^{g4}R^{g5}$, $OC(O)R^{g4}$, $OC(O)OR^{g4}$, $OC(O)SR^{g4}$, $OC(O)NR^{4g}R^{g5}$, $OC(NR^{h})NR^{g4}R^{g5}$, $SC(O)R^{g4}$, $SC(O)OR^{g4}$, $SC(O)NR^{g4}R^{g5}$, $SC(NR^{h})NR^{g4}R^{g5}$, $N(R^{h})C(O)R^{g4}$, $N[C(O)R^{g4}]_2$, $N(OR^{h})C(O)R^{g4}$, $N(R^{h})C(NR^{h1})R^{g4}$, $N(R^{h})N(R^{h1})C(O)R^{g4}$, $N[C(O)R^{g6}]NR^{g4}R^{g5}$, $N(R^{h})C(S)R^{g4}$, $N(R^{h})S(O)R^{g4}$, $N(R^{h})S(O)OR^{g4}$, $N(R^{h})S(O)_2R^{g4}$, $N[S(O)_2R^{g4}][S(O)_2R^{g5}]$, $N(R^{h})S(O)_2OR^{g4}$, $N(R^{h})S(O)_2NR^{g4}R^{g5}$, $N(R^{h})[S(O)_2]_2R^{g4}$, $N(R^{h})C(O)OR^{g4}$, $N(R^{h})C(O)SR^{g4}$, $N(R^{h})C(O)NR^{g4}R^{g5}$, $N(R^{h})C(O)NR^{h1}NR^{g4}R^{g5}$, $N(R^{h})N(R^{h1})C(O)NR^{g4}R^{g5}$, $N(R^{h})C(S)NR^{g4}R^{g5}$,

~~-[N(R^{h})C(O)][N(R^{h1})C(O)]R^{g4}, -N(R^{h})[C(O)]$_2$R^{g4}, -N{[C(O)]$_2$R^{g4}}{[C(O)]$_2$R^{g5}}, -N(R^{h})[C(O)]$_2$OR^{g4}, -N(R^{h})[C(O)]$_2$NR^{g4}R^{g5}, -N{[C(O)]$_2$OR^{g4}}{[C(O)]$_2$OR^{g4}}, -N{[C(O)]$_2$NR^{g4}R^{g5}}{[C(O)]$_2$NR^{g4}R^{g5}}, -[N(R^{h})C(O)][N(R^{h1})C(O)]OR^{g4}, -N(R^{h})C(NR^{h1})OR^{g4}, -N(R^{h})C(NOH)R^{g4}, -N(R^{h})C(NR^{h1})SR^{g4}, -N(R^{h})C(NR^{h1})NR^{g4}R^{g5}, -N(R^{h})C(=N-CN)NR^{g4}R^{g5} and -N=C(R^{h})NR^{g4}R^{g5}; and~~

~~each **R^{g}, R^{g1}, R^{g2}, R^{g3}, R^{g4}, R^{g5} and R^{g6}** independently of one another denotes hydrogen or a group selected from among C$_{1-6}$alkyl, 2-6 membered heteroalkyl, C$_{1-6}$haloalkyl, C$_{3-10}$cycloalkyl, C$_{4-16}$cycloalkylalkyl, C$_{6-10}$aryl, C$_{7-16}$arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where R^{g} together with R^{g1} and/or R^{h} may form a 3-8 membered cycloalkyl or a 3-8 membered heterocyclalkyl residue via a shared C-, N- O- or S-atom, and where **R^{g}, R^{g1}, R^{g2}, R^{g3}, R^{g4}, R^{g5} and R^{g6}** independently optionally being substituted by one or more identical or different **R^{h2}**; and~~

~~each **R^{h}, R^{h1} and R^{h2}** is selected independently of one another from among hydrogen, C$_{1-6}$alkyl, 2-6 membered heteroalkyl, C$_{1-6}$haloalkyl, C$_{3-10}$cycloalkyl, C$_{4-16}$cycloalkylalkyl, C$_{6-10}$aryl, C$_{7-16}$arylalkyl, 5-12 membered heteroaryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where **R^{h}** together with **R^{h1}** may form a 3-8 membered cycloalkyl or a 3-8 membered heterocyclalkyl residue via a shared C-, N- O- or S-atom~~, and

each **R^{5}** denotes a group selected from among **R^{m}** and **R^{n}** ; and

each **R^{m}** independently of one another denotes hydrogen or a group selected from among C$_{1-4}$alkyl, C$_{4-6}$cycloalkyl, methoxyethyl, cyclopropylmethyl, phenyl, naphthyl, benzyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, wherein **R^{m}** is optionally independently substituted by one or more identical or different **R^{n}** and/or **R^{o4}**, and

each **R^{n}** denotes a suitable group and is selected independently of one another from among =O, -OH, -OCH$_3$, -OC$_2$H$_5$, –OCF$_3$, -OCHF$_2$, –SCH$_3$, =NOH, =NOCH$_3$, -NR^{o}R^{o1}, -F, -Cl, -Br, -CF$_3$, -CN, –NO$_2$, –N$_3$, –S(O)R^{o}, -S(O)$_2$R^{o}, –C(O)R^{o}, –C(O)OR^{o}, -C(O)NR^{o}R^{o1}, -OC(O)R^{o}, –OC(O)OR^{o}, –OC(O)NR^{o}R^{o1}, -N(R^{s})C(O)R^{o}, –N(R^{s})S(O)R^{o}, –N(R^{s})S(O)$_2$R^{o}, -N(R^{s})S(O)$_2$NR^{o}R^{o1}, –N(R^{s})C(O)OR^{o}, -N(R^{s})C(O)NR^{o}R^{o1}, and

each **R^{o}, R^{o1}** and **R^{o4}** independently of one another denotes hydrogen or a group selected from among C$_{1-4}$alkyl, 2-6 membered heteroalkyl, C$_{3-6}$cycloalkyl, C$_{4-10}$cycloalkylalkyl, phenyl, benzyl, 5-6 membered heteroaryl, C$_{4-6}$heterocycloalkyl, where R^{o} together with R^{o1} and/or R^{s} may form a 3-8 membered heterocyclalkyl residue via a shared C-, N- O- or S-atom, wherein **R^{o}, R^{o1}** and **R^{o4}** is optionally independently substituted by one or more identical or different **R^{p}** and/or **R^{q4}**, and

each **R^{p}** denotes a suitable group and is selected independently of one another from among =O, -OH, methoxy, ethoxy, isopropoxy, –OCF$_3$, - OCHF$_2$, –SCH$_3$, amino, methylamino, dimethylamino, ethylamino, isopropylamino, morpholine, piperidine, pyrrolidine, piperazine, N-methylpiperazine, acetyl,

methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methoxycarbonyl, ethoxycarbonyl, -F, -Cl, -Br, $-CF_3$, –CN,

$-S(O)_2C_2H_5$, $-S(O)_2CH_3$, and

each $\mathbf{R}^{q4}$ denotes a suitable group and is independently of one another selected from among C_{1-4}alkyl, 4-6 membered heteroalkyl, C_{4-6}cycloalkyl, C_{4-7}cycloalkylalkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroarylalkyl, 4-6 membered heterocycloalkyl and 4-7 membered heterocycloalkylalkyl, and

each $\mathbf{R}^{s}$ independently of one another denotes hydrogen or a group selected from among C_{1-4}alkyl, 2-6 membered heteroalkyl, C_{3-8}cycloalkyl, C_{4-10}cycloalkylalkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-12 membered heteroarylalkyl, 3-8 membered heterocycloalkyl and 4-10 membered heterocycloalkylalkyl,

~~each $\mathbf{R}^{m}$ independently of one another denotes hydrogen or a group selected from among C_{1-6}alkyl, 2-6 membered heteroalkyl, C_{1-6}haloalkyl, C_{3-10}cycloalkyl, C_{4-16}cycloalkylalkyl, C_{6-10}aryl, C_{7-16}arylalkyl, 5-12 membered heteroaryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, and $\mathbf{R}^{m}$ optionally substituted by one or more identical or different $\mathbf{R}^{n}$ and/or $\mathbf{R}^{o4}$;~~

~~each $\mathbf{R}^{n}$ denotes a suitable group and is selected independently of one another from among =O, $-OR^{o}$, C_{1-3}haloalkyloxy, $-OCF_3$, $-OCHF_2$, =S, $-SR^{o}$, $=NR^{o}$, $=NOR^{o}$, $=NNR^{o}R^{o1}$, $=NN(R^{s})C(O)NR^{o}R^{o1}$, $-NR^{o}R^{o1}$, $-ONR^{o}R^{o1}$, $-N(OR^{o})R^{o1}$, $-N(Rs)NR^{o}R^{o1}$, halogen, $-CF_3$, -CN, -NC, -OCN, -SCN, -NO, $-NO_2$, $=N_2$, $-N_3$, $-S(O)R^{o}$, $-S(O)OR^{o}$, $-S(O)_2R^{o}$, $-S(O)_2OR^{o}$, $-S(O)NR^{o}R^{o1}$, $-S(O)_2NR^{o}R^{o1}$, $-OS(O)R^{o}$, $-OS(O)_2R^{o}$, $-OS(O)_2OR^{o}$, $-OS(O)NR^{o}R^{o1}$, $-OS(O)_2NR^{o}R^{o1}$, $-C(O)R^{o}$, $-C(O)OR^{o}$, $-C(O)SR^{o}$, $-C(O)NR^{o}R^{o1}$;~~

-C(O)N(R^s)NR^oR^o1, -C(O)N(R^s)OR^o, -C(NR^s)NR^oR^o1, -C(NOH)R^o, -C(NOH)NR^oR^o1, -OC(O)R^o, -OC(O)OR^o, -OC(O)SR^o, -OC(O)NR^oR^o1, -OC(NR^s)NR^oR^o1, -SC(O)R^o, -SC(O)OR^o, -SC(O)NR^oR^o1, -SC(NR^s)NR^oR^o1, -N(R^s)C(O)R^o, -N[C(O)R^o][C(O)R^o1], -N(OR^s)C(O)R^o, -N(R^s)C(NR^s1)R^o, -N(R^s)N(R^s1)C(O)R^o, -N[C(O)R^o2]NR^oR^o1, -N(R^s)C(S)R^o, -N(R^s)S(O)R^o, -N(R^s)S(O)OR^o, -N(R^s)S(O)2R^o, -N[S(O)2R^o][S(O)2R^o1], -N(R^s)S(O)2OR^o, -N(R^s)S(O)2NR^oR^o1, -N(R^s)[S(O)2]2R^o, -N(R^s)C(O)OR^o, -N(R^s)C(O)SR^o, -N(R^s)C(O)NR^oR^o1, -N(R^s)C(O)NR^s1NR^oR^o1, -N(R^s)N(R^s1)C(O)NR^oR^o1, -N(R^s)C(S)NR^oR^o1, -[N(R^s)C(O)]2R^o, -N(R^s)[C(O)]2R^o, -N{[C(O)]2R^o}{[C(O)]2R^o1}, -N(R^s)[C(O)]2OR^o, -N(R^s)[C(O)]2NR^oR^o1, -N{[C(O)]2OR^o}{[C(O)]2OR^o1}, -N{[C(O)]2NR^oR^o1}{[C(O)]2NR^o2R^o3}, -[N(R^s)C(O)]2OR^o, -N(R^s)C(NRs^1)OR^o, -N(R^s)C(NOH)R^o, -N(R^s)C(NR^s1)SR^o, -N(R^s)C(NR^s1)NR^oR^o1 and -N=C(R^s)NR^oR^o1 and each **R^o, R^o1, R^o2 and R^o3** independently of one another denotes hydrogen or a group selected from among C1-6alkyl, 2-6 membered heteroalkyl, C1-6haloalkyl, C3-10cycloalkyl, C4-16cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where **R^o** together with **R^o1** and/or **R^s** and/or **R^e1** and/or **R^e2** and/or **R^e3** or **R^e2** together with **R^e3** may form a 3-8 membered mono- or bicyclic heterocyclalkyl residue via a shared C-, N- O- or S-atom, or where **R^o** together with **R^o1** may form a 3-14 membered spirocyclic heterocyclalkyl residue via a shared C-, N-, O- or S-atom and where **R^o, R^o1, R^o2** and **R^o3** independently optionally being substituted by one or more identical or different **R^p** and/or **R^q4**; and

each **R^p** denotes a suitable group and is selected independently of one another from among =O, -OR^q, C1-3haloalkyloxy, -OCF3, -OCHF2, =S, -SR^q, =NR^q, =NOR^q, =NNR^qR^q1, =NN(R^s)C(O)NR^qR^q1, -NR^qR^q1, -ONR^qR^q1, -N(R^s)NR^qR^q1, halogen, -CF3, -CN, -NC, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)R^q, -S(O)OR^q, -S(O)2R^q, -S(O)2OR^q, -S(O)NR^qR^q1, -S(O)2NR^qR^q1, -OS(O)R^q, -OS(O)2R^q, -OS(O)2OR^q, -OS(O)NR^qR^q1, -OS(O)2NR^qR^q1, -C(O)R^q, -C(O)OR^q, -C(O)SR^q, -C(O)NR^qR^q1, -C(O)N(R^s)NR^qR^q1, -C(O)N(R^s)OR^q, -C(NR^s)NR^qR^q1, -C(NOH)R^q, -C(NOH)NR^qR^q1, -OC(O)R^q, -OC(O)OR^q, -OC(O)SR^q, -OC(O)NR^qR^q1, -OC(NR^s)NR^qR^q1, -SC(O)R^q, -SC(O)OR^q, -SC(O)NR^qR^q1, -SC(NR^s)NR^qR^q1, -N(R^s)C(O)R^q, -N[C(O)R^q][C(O)R^q1], -N(OR^s)C(O)R^q, -N(R^s)C(R^s1)R^q, -N(R^s)N(R^s1)C(O)R^q, -N[C(O)R^q2]NR^qR^q1,

$-N(R^s)C(S)R^q$, $-N(R^s)S(O)R^q$, $-N(R^s)S(O)OR^q$, $-N(R^s)S(O)_2R^q$, $-N[S(O)_2R^q][S(O)_2R^{q1}]$, $-N(R^s)S(O)_2OR^q$, $-N(R^s)S(O)_2NR^qR^{q1}$, $-N(R^s)[S(O)_2]_2R^q$, $-N(R^s)C(O)OR^q$, $-N(R^s)C(O)SR^q$, $-N(R^s)C(O)NR^qR^{q1}$, $-N(R^s)C(O)NR^{s1}NR^qR^{q1}$, $-N(R^s)N(R^{s1})C(O)NR^qR^{q1}$, $-N(R^s)C(S)NR^{q1}$, $-[N(R^s)C(O)][N(R^{g1})C(O)]-R^q$, $-N(R^s)[C(O)]_2R^q$, $-N\{[C(O)]_2R^q\}\{[C(O)]_2R^{q1}\}$, $-N(R^s)[C(O)]_2OR^q$, $-N(R^s)[C(O)]_2NR^qR^{q1}$, $-N\{[C(O)]_2OR^q\}\{[C(O)]_2OR^{q1}\}$, $-N\{[C(O)]_2NR^qR^{q1}\}\{[C(O)]_2NR^{q2}R^{q3}\}$, $-[N(R^s)C(O)][N(R^{s1})C(O)]OR^q$, $-N(R^s)C(NR^{s1})OR^q$, $-N(R^s)C(NOH)-R^q$, $-N(R^s)C(NR^{s1})SR^q$, $-N(R^s)C(NR^{s1})NR^qR^{q1}$, $-N(R^s)C(=N-CN)NR^qR^{q1}$ and $-N=C(R^s)NR^qR^{q1}$, and

each $\mathbf{R^q}$, $\mathbf{R^{q1}}$, $\mathbf{R^{q2}}$, $\mathbf{R^{q3}}$ and $\mathbf{R^{q4}}$ independently of one another denotes hydrogen or a group selected from among C_{1-6}alkyl, 2-6 membered heteroalkyl, C_{1-6}haloalkyl, C_{3-10}cycloalkyl, C_{4-16}cycloalkylalkyl, C_{6-10}aryl, C_{7-16}arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where $\mathbf{R^q}$ together with $\mathbf{R^{q1}}$ and/or $\mathbf{R^{q2}}$ and/or $\mathbf{R^{q3}}$ and/or $\mathbf{R^s}$ may form a 3-8 membered heterocyclalkyl residue via a shared C-, N- O- or S-atom, wherein $\mathbf{R^q}$, $\mathbf{R^{q1}}$, $\mathbf{R^{q2}}$, $\mathbf{R^{q3}}$ and $\mathbf{R^{q4}}$ are optionally independently substituted by one or more identical or different $\mathbf{R^r}$ and/or $\mathbf{R^{s4}}$, and

each $\mathbf{R^r}$ denotes a suitable group and in each case is selected independently of one another from among =O, $-OR^s$, C_{1-3}haloalkyloxy, $-OCF_3$, $-OCHF_2$, =S, $-SR^s$, $=NR^s$, $=NOR^s$, $=NNR^sR^{s1}$, $=NN(R^t)C(O)NR^sR^{s1}$, $-NR^sR^{s1}$, $-ONR^sR^{s1}$, $-N(R^h)NR^sR^{s1}$, halogen, $-CF_3$, -CN, -NC, -OCN, -SCN, -NO, $-NO_2$, $=N_2$, $-N_3$, $-S(O)R^s$, $-S(O)OR^s$, $-S(O)_2R^s$, $-S(O)_2OR^s$, $-S(O)NR^sR^{s1}$, $-S(O)_2NR^sR^{s1}$, $-OS(O)R^s$, $-OS(O)_2R^s$, $-OS(O)_2OR^s$, $-OS(O)NR^sR^{s1}$, $-OS(O)_2NR^sR^{s1}$, $-C(O)R^s$, $-C(O)OR^s$, $-C(O)SR^s$, $-C(O)NR^sR^{s1}$, $-C(O)N(R^t)NR^sR^{s1}$, $-C(O)N(R^t)OR^s$, $-C(NR^t)NR^sR^{s1}$, $-C(NOH)R^s$, $-C(NOH)NR^sR^{s1}$, $-OC(O)R^s$, $-OC(O)OR^s$, $-OC(O)SR^s$, $-OC(O)NR^sR^{s1}$, $-OC(NR^t)NR^sR^{s1}$, $-SC(O)R^s$, $-SC(O)OR^s$, $-SC(O)NR^sR^{s1}$, $-SC(NR^t)NR^sR^{s1}$, $-N(R^t)C(O)R^s$, $-N[C(O)R^s][C(O)R^{s1}]$, $-N(OR^h)C(O)R^s$, $-N(R^t)C(NR^{tt})R^s$, $-N(R^t)N(R^{tt})C(O)R^s$, $-N[C(O)R^{g2}]NR^sR^{s1}$, $-N(R^t)C(S)R^s$, $-N(R^t)S(O)R^s$, $-N(R^t)S(O)OR^s$, $-N(R^t)S(O)_2R^s$, $-N[S(O)_2R^s][S(O)_2R^{s1}]$, $-N(R^t)S(O)_2OR^s$, $-N(R^t)S(O)_2NR^sR^{s1}$, $-N(R^t)[S(O)_2]_2R^s$, $-N(R^t)C(O)OR^s$, $-N(R^t)C(O)SR^s$, $-N(R^t)C(O)NR^sR^{s1}$, $-N(R^t)C(O)NR^{tt}NR^sR^{s1}$, $-N(R^t)N(R^{tt})C(O)NR^sR^{s1}$, $-N(R^t)C(S)NR^sR^{s1}$, $-[N(R^t)C(O)][N(R^{hh})C(O)]R^s$, $-N(R^t)[C(O)]_2R^s$, $-N\{[C(O)]_2R^s\}\{[C(O)]_2R^{s1}\}$,

~~$-N(R^t)[C(O)]_2OR^s$, $-N(R^t)[C(O)]_2NR^sR^{s1}$, $-N\{[C(O)]_2OR^s\}\{[C(O)]_2OR^{s1}\}$, $-N\{[C(O)]_2NR^sR^{s1}\}\{[C(O)]_2NR^{s2}R^{s3}\}$, $-[N(R^t)C(O)][N(R^{t1})C(O)]OR^s$, $-N(R^t)C(NR^{t1})OR^s$, $-N(R^t)C(NOH)R^s$, $-N(R^t)C(NR^{t1})SR^s$, $-N(R^t)C(NR^{t1})NR^sR^{s1}$, $-N(R^t)C(=N-CN)NR^sR^{s1}$ and $-N=C(R^t)NR^sR^{s1}$; and~~

~~each R^s, R^{s1}, R^{s2}, R^{s3} and R^{s4} independently of one another denotes hydrogen or a group selected from among C_{1-6}alkyl, 2-6 membered heteroalkyl, C_{1-6}haloalkyl, C_{3-10}cycloalkyl, C_{4-16}cycloalkylalkyl, C_{6-10}aryl, C_{7-16}arylalkyl, 5-12 membered hetero-aryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where R^s together with R^{s1} and/or R^{s2} and/or R^{s3} and/or R^t may form a 3-8 membered heterocyclalkyl residue via a shared C-, N- O- or S-atom, R^s, R^{s1}, R^{s2}, R^{s3} and R^{s4} independently optionally being substituted by one or more identical or different R^{t2}; and~~

~~each R^t, R^{t1} and R^{t2} is selected independently of one another from among hydrogen, C_{1-6}alkyl, 2-6 membered heteroalkyl, C_{1-6}haloalkyl, C_{3-10}cycloalkyl, C_{4-16}cycloalkylalkyl, C_{6-10}aryl, C_{7-16}arylalkyl, 5-12 membered heteroaryl, 6-18 membered heteroarylalkyl, 3-14 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, where R^t together with R^{t1} may form a 3-8 membered heterocyclalkyl residue via a shared C-, N-, O- or S-atom, and~~

~~each R^v and R^{v1} is selected independently of one another from among hydrogen, C_{1-6}alkyl, 2-6 membered heteroalkyl, C_{1-6}haloalkyl, where R^v together with R^{v1} may form a 3-8 membered heterocyclalkyl residue via a shared C-, N- O- or S-atom,~~

optionally in the form of ~~the prodrugs,~~ the tautomers, the racemates, the enantiomers, the diastereomers~~,~~ ~~the prodrugs~~ and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.

~~2. Compounds according to Claim 1, wherein R^2 denotes a group selected from among C_{3-8}cycloalkyl, 3-8 membered heteroalkyl, 3-8 membered heterocycloalkyl, OR^v, NR^vR^{v1}, CF_3, CN, NC and NO_2.~~

~~3. Compounds according to claim 1, wherein R^2 denotes C_{1-4}-alkyl.~~

~~4.~~ 2. Compounds according ~~to any of~~ claims ~~1 to 3~~, wherein $\mathbf{R^2}$ denotes $-CH_3$ or $-C_2H_5$.

5. Compounds according to any of claims 1 to 4, wherein $\mathbf{R^1}$ denotes phenyl or pyridyl, optionally substituted by one or more identical or different $\mathbf{R^5}$.

6. Compounds according to any of claims 1 to 5 wherein $\mathbf{R^5}$ denotes a group selected from among $\mathbf{R^m}$, $\mathbf{R^n}$; and

each $\mathbf{R^m}$ independently of one another denotes hydrogen or a group selected from among C_{1-4}alkyl, C_{4-6}cycloalkyl, methoxyethyl, cyclopropylmethyl, phenyl, naphthyl, benzyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl, wherein $\mathbf{R^m}$ is optionally independently substituted by one or more identical or different $\mathbf{R^n}$ and/or $\mathbf{R^{o4}}$, and

each $\mathbf{R^n}$ denotes a suitable group and is selected independently of one another from among =O, -OH, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-OCHF_2$, $-SCH_3$, =NOH, $=NOCH_3$, $-NR^oR^{o1}$, -F, -Cl, -Br, $-CF_3$, -CN, $-NO_2$, $-N_3$, $-S(O)R^o$, $-S(O)_2R^o$, $-C(O)R^o$, $-C(O)OR^o$, $-C(O)NR^oR^{o1}$, $-OC(O)R^o$, $-OC(O)OR^o$, $-OC(O)NR^oR^{o1}$, $-N(R^s)C(O)R^o$, $-N(R^s)S(O)R^o$, $-N(R^s)S(O)_2R^o$, $-N(R^s)S(O)_2NR^oR^{o1}$, $-N(R^s)C(O)OR^o$, $-N(R^s)C(O)NR^oR^{o1}$, and

each $\mathbf{R^o}$, $\mathbf{R^{o1}}$ and $\mathbf{R^{o4}}$ independently of one another denotes hydrogen or a group selected from among C_{1-4}alkyl, 2-6 membered heteroalkyl, C_{3-6}cycloalkyl, C_{4-10}cycloalkylalkyl, phenyl, benzyl, 5-6 membered heteroaryl, C_{4-6}heterocycloalkyl, where R^o together with R^{o1} and/or R^s may form a 3-8 membered heterocyclalkyl residue via a shared C-, N- O- or S-atom, wherein $\mathbf{R^o}$, $\mathbf{R^{o1}}$ and $\mathbf{R^{o4}}$ is optionally independently substituted by one or more identical or different $\mathbf{R^p}$ and/or $\mathbf{R^{q4}}$, and

each $\mathbf{R^p}$ denotes a suitable group and is selected independently of one another from among =O, -OH, methoxy, ethoxy, isopropoxy, $-OCF_3$, $-OCHF_2$, $-SCH_3$, amino, methylamino, dimethylamino, ethylamino, isopropylamino, morpholine, piperidine, pyrrolidine, piperazine, N-methylpiperazine, acetyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methoxycarbonyl, ethoxycarbonyl, -F, -Cl, -Br, $-CF_3$, -CN, $-S(O)_2C_2H_5$, $-S(O)_2CH_3$, and

each $\mathbf{R^{q4}}$ denotes a suitable group and is independently of one another selected from among C_{1-4}alkyl, 4-6 membered heteroalkyl, C_{4-6}cycloalkyl, C_{4-7}cycloalkylalkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-8 membered heteroarylalkyl, 4-6 membered

~~heterocycloalkyl and 4-7 membered heterocycloalkylalkyl, and~~

~~each R^s independently of one another denotes hydrogen or a group selected from among C_{1-4}alkyl, 2-6 membered heteroalkyl, C_{3-8}cycloalkyl, C_{4-10}cycloalkylalkyl, phenyl, benzyl, 5-6 membered heteroaryl, 6-12 membered heteroarylalkyl, 3-8 membered heterocycloalkyl and 4-10 membered heterocycloalkylalkyl.~~

~~7.~~3. Compounds according to ~~any of~~ claims ~~1 to 6~~or 2, wherein each $\mathbf{R^{q4}}$ denotes a suitable group and is independently of one another selected from among methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, tert-butyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, methoxyethyl, phenyl, benzyl, pyridyl, pyrimidinyl, pyridazinyl, imidazolyl, pyrazolyl, thiazolyl.

~~8.~~4. Compounds according to any of claims 1 to ~~7~~3, wherein $\mathbf{R^5}$ denotes a group selected from among R^n, and

each $\mathbf{R^n}$ denotes a suitable group and is selected independently of one another from among methoxy, ethoxy, -F, -Cl, $-C(O)R^o$, $-C(O)NR^oR^{o1}$, and

each $\mathbf{R^o}$ **and** $\mathbf{R^{o1}}$ independently of one another denotes hydrogen or a group selected from among methyl, ethyl, prop-2-yl, prop-1-yl, methoxyethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, morpholine, piperidine, pyrolidine, piperazine, or where $\mathbf{R^o}$ **and** $\mathbf{R^{o1}}$ form a cyclic amine, selected from morpholine, piperazine, homomorpholine, homopiperazine, piperidine, pyrolidine, wherein $\mathbf{R^o}$ and $\mathbf{R^{o1}}$ are independently optionally substituted by one or more identical or different $\mathbf{R^p}$ and/or $\mathbf{R^{q4}}$,and

each $\mathbf{R^p}$ denotes a suitable group and is selected independently of one another from among =O, -OH, methoxy, ethoxy, isopropoxy, amino, methylamino, dimethylamino, ethylamino, isopropylamino, acetyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methoxycarbonyl, ethoxycarbonyl, -F, -Cl, -Br, $-CF_3$, –CN, and

each $\mathbf{R^{q4}}$ denotes a suitable group and is independently of one another selected from among methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, tert-butyl, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, N-methylpiperazinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, 1,1-dioxo-tetrahydrothiophenyl, cyclopropyl,

cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, methoxyethyl, phenyl, benzyl, pyridyl, pyrimidinyl, pyridazinyl, imidazolyl, pyrazolyl, thiazolyl.

~~9.~~5. Compounds according to any of claims 1 to ~~8~~4, wherein $\mathbf{R^1}$ denotes pyridyl, and wherein R^5 and $\mathbf{R^5}$ are selected from among methyl, ethyl, n-propyl, isopropyl, cyclopropyl, methoxy, $-CF_3$.

~~10.~~6. Compounds according to any of claims 1 to ~~8~~4, wherein $\mathbf{R^1}$ denotes phenyl, and wherein R^5 wherein $\mathbf{R^5}$ are selected from among R^n, and

each $\mathbf{R^n}$ denotes a suitable group and is selected independently of one another from among methyl, methoxy, ethoxy, -F, -Cl, $-C(O)R^o$, $-C(O)NR^oR^{o1}$, and

each $\mathbf{R^o}$ **and** $\mathbf{R^{o1}}$ independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different $\mathbf{R^p}$ **and/or** $\mathbf{R^{q4}}$, selected from among methyl, ethyl, prop-2-yl, prop-1-yl, methoxyethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, morpholine, piperidine, pyrolidine, piperazine, or where $\mathbf{R^o}$ **and** $\mathbf{R^{o1}}$ form a cyclic amine, selected from morpholine, piperazine, homomorpholine, homopiperazine, piperidine, pyrolidine, optionally substituted by one or more identical or different $\mathbf{R^p}$ **and/or** $\mathbf{R^{q4}}$,and

each $\mathbf{R^p}$ denotes a suitable group and is selected independently of one another from among =O, -OH, methoxy, ethoxy, isopropoxy, amino, methylamino, dimethylamino, ethylamino, isopropylamino, acetyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methoxycarbonyl, ethoxycarbonyl, -F, -Cl, -Br, $-CF_3$, –CN, and

each $\mathbf{R^{q4}}$ denotes a suitable group and is independently of one another selected from among methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, tert-butyl, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, N-methylpiperazinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, 1,1-dioxo-tetrahydrothiophenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, methoxyethyl, phenyl, benzyl, pyridyl, pyrimidinyl, pyridazinyl, imidazolyl, pyrazolyl, thiazolyl.



~~11. Compounds according to any of claims 1 to 10, wherein R^3 denotes phenyl or pyridyl, optionally substituted by one or more identical or different R^4.~~







~~12. Compounds according to any of claims 1 to 11, wherein R^3 denotes pyridyl, optionally substituted by one or more identical or different R^4.~~







~~13. Compounds according to any of claims 1 to 12 wherein R^4 denotes a group selected from among R^a, R^b and R^a substituted by one or more identical or different R^b and/or R^c; and each R^a independently of one another is selected from among hydrogen, methyl, ethyl, and each R^b denotes a suitable group and is selected independently of one another from among OCH_3, NH_2, $NHCH_3$, NHC_2H_5, F, Cl, Br, CF_3, CN,.~~







~~14. Compounds according to any of claims 1 to 13, wherein R^3 denotes pyridyl and wherein R^4 and R^4 are selected from among methyl, ethyl, amino, methylamino, ethylamino.~~









~~15.~~7. Compounds according to any of claims 1 to~~14~~ 6 selected from







Nr.	Structure	Nr.	Structure
~~E-1~~		~~E-2~~	







Nr.	Structure	Nr.	Structure
E-3		E-5	
E-6		E-7	
E-9		E-14	







Nr.	Structure	Nr.	Structure
E-18		E-20	
E-70		E-71	
E-72		E-150	







Nr.	Structure	Nr.	Structure
E-153		E-160	
E-161		E-162	
E-165		E-178	







Nr.	Structure	Nr.	Structure
E-179		E-182	
E-183		E-184	
E-185		E-186	
E-189		E-191	







Nr.	Structure	Nr.	Structure
E-197		E-198	
E-199		E-210	
E-211		E-212	









Nr.	Structure	Nr.	Structure
E-215		E-216	
E-233		E-234	
E-235		E-236	









Nr.	Structure	Nr.	Structure
E-240		E-245	
E-252		E-259	
E-265		E-271	







Nr.	Structure	Nr.	Structure
E-273		E-275	
E-280		E-282	
E-287		E-288	









Nr.	Structure	Nr.	Structure
E-291		E-292	
E-294		E-296	
E-298		E-299	







Nr.	Structure	Nr.	Structure
E-301		E-305	
E-306		E-308	
E-309		E-313	

~~Nr.~~	~~Structure~~	~~Nr.~~	~~Structure~~
~~E-314~~		~~E-316~~	
~~E-317~~		~~E-347~~	
~~E-348~~		~~E-349~~	
D-8		D-13	







Nr.	Structure	Nr.	Structure
D-15		D-20	
D-21		D-28	
D-29		D-31	
D-38		D-42	







Nr.	Structure	Nr.	Structure
D-45		D-58	
D-63		D-64	
D-70		D-78	

Nr.	Structure	Nr.	Structure
D-83		D-84	
D-95		D-96	
D-106		D-121	
D-122		D-151	


Nr.	Structure	Nr.	Structure
D-79		D-236	
D-237		D-239	
~~E-4~~		~~E-70~~	

8. A compound according to claim 7 selected from:

D-28		D-29	
D-31		D-38	
D-42		D-58	

D-63		D-64	
D-83		D-84	
D-79		D-239	


9. A compound selected from:



D-28

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.


10. A compound selected from:



D-29

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.


11. A compound selected from:



D-31

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.


12. A compound selected from:



D-38

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.


13. A compound selected from:



D-42

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.


14. A compound selected from:



D-58

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.


15. A compound selected from:



D-63

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.


16. A compound selected from:



D-64

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.


17. A compound selected from:



D-83

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.


18. A compound selected from:



D-84

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.


19. A compound selected from:



D-79

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.

20. A compound selected from:



D-239

optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers, and the mixtures thereof, and optionally the pharmacologically acceptable salts thereof.

~~16.~~ 21. Compounds, or the pharmacologically effective salts thereof, according to any one of claims 1 to 20~~15~~, as medicaments.

~~17.~~22. Compounds, or the pharmacologically effective salts thereof, according to any one of claims 1 to ~~15~~20, for preparing a medicament with an antiproliferative activity.

~~18.~~23. Pharmaceutical preparations, containing as active substance one or more compounds of general formula (1) according to any one of claims 1 to ~~15~~ 20 or the pharmacologically effective salts thereof, optionally in combination with conventional excipients and/or carriers.

~~19.~~24. Compounds of general formula (1) according to any one of claims 1 to 20 ~~15~~ for use in the treatment and/or prevention of cancer, infections, inflammatory and autoimmune diseases

~~20.~~25. Use of compounds of general formula (1) according to any one of claims 1 to 20 ~~15~~ for preparing a medicament for the treatment and/or prevention of cancer, infections, inflammatory and autoimmune diseases.

~~21.~~26. Pharmaceutical preparation comprising a compound of general formula (1) according to any one of claims 1 to 20 ~~15~~ and at least one other cytostatic or cytotoxic active substance, different from formula (1), optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, as well as optionally the pharmacologically acceptable salts thereof.